

PRELIMINARY PROGRAM

Immunotherapy Bridge
Royal Continental Hotel, Naples
29th-30th November, 2017

**to be confirmed*

09:00 – 09:20 Registration

November 29th (Wednesday)

Session I - System biology session: Immunology

Chairpersons: Igor Puzanov, Ena Wang

09:20 – 09:35 Introduction and objectives, Paolo A. Ascierto

09:35 – 09:55 Development of cancer vaccine for liver cancer, Luigi Buonaguro

09:55 – 10:15 Multispectral imaging, cancer vaccines and a strategy to develop combination immunotherapy with T cell agonists, Bernard Fox

10:15 – 10:35 Novel combinatorial immunotherapies with PD-1 blockade from the bench into the clinic, Hassane Zarour

10:35 – 10:55 The search for blood-based biomarkers to predict immunotherapy outcomes, Ryan Sullivan

10:55 – 11:15 Genomics and immunotherapy: tumor mutation burden, mutations affecting antigen presentation, immune recognition, and genome integrity*, Davide Carbone

11:15 – 11:25 Discussion

11:25 – 11:40 Break

11:40 – 12:40 Oral Communications (NO CME)*

12:40 – 13:10 The role of tumor immune microenvironment*, Ignacio Melero Barmejo, Paolo A. Ascierto

13:10 – 13:20 Discussion

13:20 – 13:40 Conclusions, Igor Puzanov, Ena Wang

13:40 – 14:25 Lunch

Session II - Immunotherapy Beyond Melanoma

Chairpersons: Heinz Zwierzina, Fortunato Ciardiello

14:25 – 15:25 Symposium – Title to be defined

Opening*, Paolo A. Ascierto

Head & Neck*, Marco Merlano

Bladder*, Giacomo Carteni*

Immunocorrelated adverse events*, Mario Mandalà

15:25 – 15:45 Immunotherapy for advanced NSCLC: state of the art, Cesare Gridelli

15:45 – 16:05 Biomarker driven immunotherapy for H&N cancer, Robert Ferris

16:05 – 16:25 The differences between immunotherapy for renal cancer and immunotherapy for melanoma, Paul Nathan

16:25 – 16:45 Which role for immunotherapy in the treatment of hepatocellular carcinoma?, Bruno Daniele

16:45 – 16:55 Discussion

16:55 – 17:10 Break

17:10 – 18:10 Oral Communications (NO CME)*

18:10 – 18:30 Conclusions, Heinz Zwierzina, Fortunato Ciardiello

November 30th (Thursday)

Session III - SITC Session - Evolving Topics in Cancer Immunotherapy

Chairperson: Lisa H. Butterfield

- 09:30 – 09:50 DC Vaccine Combinations for Melanoma, Lisa H. Butterfield
- 09:50 – 10:10 The Next Generation of Oncolytic Viruses for the Treatment of Melanoma, Howard Kaufman
- 10:10 – 10:30 Engineering durability and sustainability into adoptively transferred T cells, Christopher A. Klebanoff
- 10:30 – 10:50 Generate long-lived memory T cells for effective cancer immunotherapy, Crystal M. Paulos
- 10:50 – 11:00 Discussion
- 11:00 – 11:15 Break
- 11:15 – 12:45 Oral Communications (NO CME)
- 12:45 – 13:05 Conclusions, Lisa H. Butterfield
- 13:05 – 13:50 Lunch

Session IV - Immunotherapy in Oncology: Data from clinical trials

Chairpersons: Sandro Pignata, Alfredo Budillon

- 13:50 – 14:10 Tumor/stroma interaction: lessons learnt from an inflamed tumor type, James Brugarolas
- 14:10 – 14:30 Chimeric-antigen receptor T cells for hematological malignancies: building upon CART19, Marco Ruella
- 14:30 – 14:50 Consequences of rapid evolution of adjuvant therapy landscape in melanoma, Alexander Eggermont
- 14:50 – 15:10 Immunotherapy for Breast Cancer: Rationale and Recent Clinical Trial Results, Rita Nanda
- 15:10 – 15:30 System immunology to decipher the tumor microenvironment, Jerome Galon
- 15:30 – 15:40 Discussion
- 15:40 – 15:55 Break
- 15:55 – 16:55 Oral Communications (NO CME)*
- 16:55 – 17:20 Conclusions, Sandro Pignata, Alfredo Budillon

Presidency

Paolo A. Ascierto - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Igor Puzanov - Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Clinical Research, Director of Early Clinical Trials and Developmental Therapeutics, Director of Melanoma Program, Professor of Medicine and Oncology at Roswell Park Cancer Institute in Buffalo, New York

Ena Wang - Division Chief of Translational Medicine, Sidra Medical and Research Centre, Doha, Qatar

Scientific Board

Sanjiv Agarwala - Chief of Medical oncology and Haematology, St. Luke's University Hospital and Temple University, Bethlehem, Pennsylvania

Paolo A. Ascierto - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Carlo Bifulco - Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon

Sandra Demaria - New York University School of Medicine and NYU Langone Medical Center Alexandria Center for Life Sciences, New York, New York

Reinhard Dummer - Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

Bernard A. Fox - Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon

Jerome Galon - Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

Claus Garbe - University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany

Giuseppe Masucci - Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

Michael Postow - Memorial Sloane Kettering Cancer Center, New York, New York

Igor Puzanov - Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Clinical Research, Director of Early Clinical Trials and Developmental Therapeutics, Director of Melanoma Program, Professor of Medicine and Oncology at Roswell Park Cancer Institute in Buffalo, New York

Magdalena Thurin - Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland

Ena Wang - Division Chief of Translational Medicine, Sidra Medical and Research Centre, Doha, Qatar

Invited Faculty

Paolo A. Ascierto - Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Alfredo Budillon - Oncological Experimental Pharmacology Unit Director, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Luigi Buonaguro - Unit of Molecular Biology and Viral Oncology, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy

Lisa H. Butterfield - SITC, University of Pittsburgh, Pennsylvania, US

James Brugarolas – Director of the kidney cancer program, Associate Professor of Internal Medicine, Cancer Biology, Genetics, Development and Disease, UT Southwestern Medical Center, The University of Texas Southwestern Medical Center, Dallas, Texas, US

Giacomo Carteni – Director of Medical Oncology, Cardarelli Hospital, Naples, Italy

Fortunato Ciardiello - ESMO President - Full Professor of Medical Oncology, Head of the Laboratory of Experimental Therapeutics, Head of the Division of Medical Oncology, Seconda Università di Napoli, Naples, Italy

Bruno Daniele - Department Director of Oncology - U.O.C. of Medical Oncology, G. Rummo Hospital, Benevento, Italy

Alexander Eggermont - Institut de Cancérologie Gustave Roussy, Villejuif, Paris-Sud, France

Robert J. Ferris - UPMC Endowed Professor and Chief, Division of Head and Neck Surgery, Department of Otolaryngology, University of Pittsburgh, Pennsylvania, US

Bernard A. Fox -Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon

Jerome Galon - Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

Cesare Gridelli – UOSC of Medical Oncology Director, Hospital San Giuseppe Moscati, Avellino, Italy

Roy Herbst - Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology, Chief of Medical Oncology, Yale Cancer Center, New Haven

Marco Ruella - Clinical Instructor, Associate Director Dr. June's Laboratory, Center for Cellular Immunotherapies (CCI), Perelman School of Medicine, University of Pennsylvania, Smilow Center for Translational Research, Philadelphia, Pennsylvania, US

Howard Kaufman – Professor of Surgery, Robert Wood Johnson Medical School Rutgers, The State University of New Jersey, New Jersey, US

Christopher A. Klebanoff - Medical Oncologist, Head, Breast Immunotherapy Section, Memorial Sloan-Kettering Cancer Center, New York, New York, US

Mario Mandalà – Oncology Unit Director, Papa Giovanni XXII Hospital, Bergamo, Italy

Ignacio Javier Melero Barmejo – Co-director of the Immunology and Immunotherapy Service, University Clinic of Navarra, Pamplona, Navarra, Spain

Marco Merlano - Oncology Department Director AO S. Croce & Carle, Cuneo, , Italy

Rita Nanda - Assistant Professor of Medicine, Associate Director, Breast Medical Oncology, The University of Chicago Medicine, Chicago

Paul Nathan - Consultant Medical Oncologist, Mount Vernon Cancer Centre

Crystal M. Paulos - SITC, Medical University of South Carolina, US

Sandro Pignata -Director of Uro-Gynecological Oncology Department, National Cancer Institute “Fondazione G. Pascale” of Naples, Italy

Igor Puzanov - Associate Professor of Medicine, Associate Director of Phase I Drug Development, Director, Melanoma Clinical Research, Director of Early Clinical Trials and Developmental Therapeutics, Director of Melanoma Program, Professor of Medicine and Oncology at Roswell Park Cancer Institute in Buffalo New York

Ryan J. Sullivan - Assistant Professor, Medicine, Harvard Medical School, Assistant Professor, Haematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts

Ena Wang - Division Chief of Translational Medicine, Sidra Medical and Research Centre, Doha, Qatar

Hassane Zarour – Professor of Medicine, Immunology and Dermatology, Co-Leader, Melanoma Program, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pennsylvania, US

Heinz Zwierzina -Chairman of the CDDF – Cancer Drug Development Forum and Professor of Internal Medicine at Innsbruck University in Austria